Lung Cancer
(FURMO-004) A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations
- Details
ClinicalTrials.gov ID:
NCT05607550
Diagnosis Type:
NA
USOR Number:
- Address
12123 SW 69th Avenue
Tigard, OR 97223
P: (971) 708-7600